The landmark FDA approval of the first MASH therapeutic, the orphan drug designation for systemic sclerosis trials, and the rapid advancement of IPF treatments through clinical phases have ignited a transformative era in fibrosis research. Now more than ever experts are doubling down on fibrosis.
As the focus on innovative therapies intensifies, there is a pressing need for cutting-edge strategies that can overcome preclinical and clinical challenges has never been more critical. With that, I’m delighted to announce the return of the 𝗔𝗻𝘁𝗶𝗳𝗶𝗯𝗿𝗼𝘁𝗶𝗰 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁 for its 𝟴𝘁𝗵 𝘆𝗲𝗮𝗿 as the fibrosis community’s premier event, uniting industry experts and key opinion leaders across Pulmonology, Hepatology, Rheumatology, Nephrology, Cardiology, and Gastroenterology.
Gathering decision makers to share cross fibrosis insights on innovative strategies to navigate the shared fibrosis challenges from discovery to novel targets, preclinical models, biomarkers, and early-stage clinical trials. Gain exclusive insights and strategies to apply to your own research accelerating the development of truly transformative, disease-modifying, ‘antifibrotic’ therapeutics.
Whether focusing on 𝗜𝗣𝗙, 𝗠𝗔𝗦𝗛, 𝘀𝘆𝘀𝘁𝗲𝗺𝗶𝗰 𝘀𝗰𝗹𝗲𝗿𝗼𝘀𝗶𝘀, 𝗸𝗶𝗱𝗻𝗲𝘆 𝗳𝗶𝗯𝗿𝗼𝘀𝗶𝘀, 𝗰𝗮𝗿𝗱𝗶𝗮𝗰 𝗳𝗶𝗯𝗿𝗼𝘀𝗶𝘀, 𝗳𝗶𝗯𝗿𝗼𝘀𝗶𝗻𝗴 𝗜𝗕𝗗 or 𝗮𝗻𝗼𝘁𝗵𝗲𝗿, this summit is your collective forum to propel innovative and efficacious antifibrotic therapeutics to patients in need.
Join us at the 8th AFDD Summit to be part of the conversation, share your insights, and discover the innovations that are transforming fibrosis treatment.
To know more visit: https://ter.li/01itbv